Urine albumin dipstick independently predicts cardiovascular and renal outcomes among rural Thai population: a 14-year retrospective cohort study

Noppawit Aiumtrakul1*, Kitinan Phichedwanichskul1, Surapong Saravutthikul1, Kamonwan Ottasat1, Kesinee Visuthitepkul1, Thitinat Jaruthiti1, Sarita Jinawong1, Kwanchanok Chanthowong1, Varot Pongsritong1, Nattawinee Horadee1, Chotip Jitudomtham1, Torpathom Pruekprasert1, Thakorn Tawatkitipol1, Tunjira Chokjutha1, Panuwat Pongpripoom1, Chirayu Wiwatwarapon1, Pirawich Sriyarun1, Natcha Homrossukhon1, Annop Kittithaworn1, Wisit Kaewput1, Ram Rangsin1 and Bancha Satirapoj2

Abstract

Background: Albuminuria is an established risk marker for both cardiovascular and renal outcomes. In this study, we expected to use portable and inexpensive test strips to detect urine albumin level for risk stratification in cardiovascular and renal outcomes among rural Thai community.

Objective: To evaluate the relationship between urine albumin dipstick and cardiovascular and renal complications in rural Thai population.

Methods: We conducted a retrospective study in 635 rural Thai adults who tested urine albuminuria by using commercial urine albumin dipstick and the Micral-albumin test II strips at baseline. The subjects were divided into normoalbuminuria (albumin < 20 mg/L), microalbuminuria (albumin 20–200 mg/L), or macroalbuminuria (Urine dipstick at least 1+ or albumin > 200 mg/L). We collected data on the incidences of primary composite outcomes including cardiovascular or renal morbidity and mortality. Incident density and cox regression were analyzed to evaluate the association between albuminuria status and primary composite outcome.

(Continued on next page)
Introduction
The presence of urine albumin reflects endothelial and vascular damage [1]. Albuminuria is an established risk marker for both cardiovascular and renal outcomes [2–9] not only in diabetes patients [10, 11] but also in hypertension [12, 13] and in the general population [14, 15]. Some studies also showed microalbuminuria as an independent predictor for cardiovascular and all-cause mortality [14, 16]. In developed countries, independent association between dipstick proteinuria and an increase in cardiovascular morbidity or all-cause mortality among adult were demonstrated in several studies [17–21]. However, there are limited data about proteinuria and its cardiovascular outcome in developing country [22] where the cost-effective screening test should be performed, especially in primary care setting. In this study, we expected to use portable and inexpensive test strips to detect urine albumin level for risk stratification in cardiovascular and renal outcomes among rural Thai community.

Materials and methods
Subjects
A retrospective cohort study was conducted in 755 rural Thai population aged 35 years and older at Moo 15 Baan Nayao Thakadan Subdistrict, Sanamchaikhet District, Chacherngsao Province, Thailand since February 2004. The study protocol was approved by the Institutional Review Board of Royal Thai Army Medical Department’s committee on human research, and written informed consent was obtained from all subjects. Exclusion criteria are pregnancy, having menstrual period, urinary tract infection, pyuria, nephrolithiasis, hematuria, history of coronary artery disease (CAD), history of stroke, end-stage renal disease (ESRD) and subjects who were unable to collect first-spot morning urine or did not have information on dipstick proteinuria. Therefore, 635 subjects were enrolled which consisted of 452, 155 and 28 individuals in Normoalbuminuria, Microalbuminuria and Macroalbuminuria group, respectively (Fig. 1). To study the effect of albuminuria on cardiovascular outcomes, especially mortality, a study by Valmadrid et al. in 2000 was referred [23]. Sample size needed 142, 71 and 36 individuals in Normoalbuminuria, Microalbuminuria and Macroalbuminuria group, respectively.

Data collection
At baseline, demographic data were obtained using standardized questionnaire including age, gender, weight, height, blood pressure, history of smoking, diabetes, hypertension dyslipidemia and current medication. According to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), hypertensive subjects were defined by office blood pressure measurement with systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg. For medication, ACEI/ARBs included enalapril and losartan, sulfonylurea included glipezide and glibenclamide, beta-blockers included atenolol, propranolol and metoprolol and diuretics included hydrochlorothiazide, furosemide and spironolactone. These agents were all available medication in primary care centers around the rural community. First-morning spot urine and venipuncture were done for urine dipstick and serum creatinine testing respectively. All urine samples were examined by Micral test to stratify urine albumin group. Subjects who had urine microalbumin less than 20 mg/L defined as “Normoalbuminuria”, for those who had Micral test equal to or over than 20 mg/L will be continually tested by Combur UX urine dipstick. If the samples had urine microalbumin equal to or less than 200 mg/L, the subjects would be defined as “Microalbuminuria”, for those who had over 200 mg/L, they would be defined as “Macroalbuminuria” group. Serum creatinine was tested by enzymatic method. eGFR (in ml/min per 1.73 m2) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) [24].

Results: During an average 14-year follow-up, 102 primary composite events occurred including 59 (13.1%), 32 (20.6%) and 11 (39.3%) among 452, 155, and 28 subjects with normoalbuminuria, microalbuminuria, and macroalbuminuria, respectively. Incident densities of primary composite outcome were elevated continually according to the degree of albuminuria (9.36, 17.11 and 38.12 per 1000 person-years). Compared with the subjects without albuminuria, subjects with microalbuminuria and macroalbuminuria at baseline had higher risk for primary composite outcome in univariate model. After multivariate analysis was performed, the effect of macroalbuminuria was only persisted with 3.13-fold risk (adjusted HR 3.13; 95% CI 1.40–6.96, P= 0.005).

Conclusion: Albuminuria from semi-quantitative methods is an important factor predicting cardiovascular and renal risk among subjects in Thai rural population. Our findings support to also incorporating urine albumin dipstick into assessments of cardiovascular risk in the general population.

Keywords: Microalbuminuria, Cardiovascular outcomes, Chronic kidney disease
In December 2017, information about cardiovascular events, renal events and all-cause mortality were collected from electronic medical record (EMR) in primary care hospitals nearby, district office and home visit.

Outcome definition
Primary composite outcome of the study consists of cardiovascular or renal morbidity and mortality. Secondary composite outcome consists of cardiovascular or renal morbidity and all-cause mortality. International Classification of Diseases 10 (ICD-10) codes were identified in the hospital database to collect the outcome from EMR. Cardiovascular event was defined as ICD-I00 to ICD-I52 or ICD-I60 to ICD-I69. Renal event was defined as ICD-N00 to N19 or eGFR lower than 15 mL/min/1.73 m2 or initiation of renal replacement therapy. Information of mortality was obtained from EMR, district office and home visit. The duration between the baseline date and date of first event in each individual was the calculated follow-up time.

Statistical analysis
Data were analyzed using IBM SPSS 22.0 (SPSS, Chicago, IL, USA). Baseline characteristics of subjects were analyzed using descriptive statistics. Categorical data were presented as number with percentage while continuous data were presented as means with standard deviation. ANOVA test was used to compare continuous variables and Chi-square test was used for categorical variables among albuminuria groups. Incident density was calculated and reported as the number of events per 1000 person-years for both primary and secondary composite outcomes. Kaplan-Meier analysis and log-rank test were used for both of the composite outcomes. Cox proportional hazard model for multivariate analysis, adjusting for age, gender, type 2 diabetes, hypertension, eGFR, aspirin, ACEI/ARBs, insulin and metformin at baseline, on both of the composite outcomes was calculated and reported as hazard ratio (HR) with 95% confidence intervals (CI), involving survival time to the first event of any subjects. P-values were two-sided and statistical significance was indicated for p-value < 0.05.
**Results**

We identified 452, 155, and 28 subjects with normoalbuminuria, microalbuminuria and macroalbuminuria, respectively. The subjects in each group had similar characteristic in age, gender, smokers, dyslipidemia patient and the use of beta-blockers, amlodipine, diuretics, sulfonylurea, metformin, simvastatin and gemfibrozil. BMI, blood pressure, hypertensive patient, diabetic patient and the use of ACEI/ARBs, insulin and aspirin were different with higher value as higher level of albuminuria group, except serum creatinine that lower among microalbuminuria than normoalbuminuria group (Table 1).

The frequency of clinical outcomes and the incident densities of both composite outcomes were increased consecutively according to the degree of albuminuria (Tables 2, 3 and 4).

Univariate analysis of cox regression model in primary composite outcome, compared with the subjects without albuminuria, subjects with microalbuminuria and macroalbuminuria at baseline had a 1.82-fold and 4.09-fold respectively higher risk for cardiovascular or renal morbidity and mortality (unadjusted HR 1.82; 95% CI 1.15–2.89, \(P = 0.011\) and unadjusted HR 4.09; 95% CI 2.21–7.88, \(P = <0.001\)). Significant associations were also found in age, gender, type 2 diabetes, hypertension, serum creatinine, eGFR and the use of aspirin, ACEI/ARBs, insulin and metformin as well. In multivariate model, macroalbuminuria, hypertension and aspirin were still significant with 3.13-fold, 2.6-fold and 5.28-fold higher risk respectively (adjusted HR 3.13; 95% CI 1.4–6.96, \(P = 0.005\), adjusted HR 2.6; 95% CI 1.35–5.0, \(P = 0.004\) and adjusted HR 5.28; 95% CI 2.75–10.14), whereas, metformin significantly reduced risk for 0.29-fold (adjusted HR 3.31; 95% CI 0.09–0.94) after adjusting for age, gender, type 2 diabetes, hypertension, eGFR, aspirin, ACEI/ARBs, insulin and metformin, (Table 5).

For secondary composite outcome, univariate cox regression analysis revealed similar trend and significant variables as the previous model, except microalbuminuria. Multivariate analysis with the same adjusting factors showed that age, hypertension and aspirin were significantly associated with the outcome with 1.05-fold, 1.9-fold and 2.08-fold risk respectively. (adjusted HR 1.05; 95% CI 1.02–1.07, \(P = <0.001\), adjusted HR 1.9; 95% CI 1.16–3.11, \(P = 0.011\) and adjusted HR 2.08; 95%

**Table 1** Baseline characteristics

| Urine albumin status | Normoalbuminuria (n=452) | Microalbuminuria (n=155) | Macroalbuminuria (n=28) | \(P\)- value |
|----------------------|--------------------------|--------------------------|-------------------------|-------------|
| Age (years)          | 50.48 ± 11.45            | 51.06 ± 11.31            | 53.57 ± 12.46           | 0.359       |
| Male (%)             | 197 (43.6%)              | 70 (45.2%)               | 12 (42.9%)              | 0.937       |
| BMI (kg/m²)          | 23.54 ± 3.91             | 24.42 ± 3.93             | 25.88 ± 4.61            | 0.016       |
| Systolic BP (mmHg)   | 121.2 ± 16.45            | 122.49 ± 16.71           | 129.38 ± 21.48          | 0.048       |
| Diastolic BP (mmHg)  | 77.5 ± 9.19              | 79.58 ± 10.29            | 83.46 ± 13.27           | 0.002       |
| History of Hypertension | 112 (24.8%)        | 50 (32.3%)               | 14 (50%)                | 0.005       |
| History of Type2 DM  | 38 (8.4%)                | 21 (13.5%)               | 7 (25%)                 | 0.007       |
| History of Dyslipidemia | 39 (8.6%)             | 10 (6.5%)                | 4 (14.3%)               | 0.356       |
| History of smoking (%) | 87 (19.2%)           | 37 (23.9%)               | 4 (14.3%)               | 0.340       |
| Serum creatinine (mg/dL) | 0.71 ± 0.19            | 0.68 ± 0.14              | 0.95 ± 0.48             | <0.001      |
| eGFR (ml/min/1.73m²) | 91.69 ± 18.85            | 93.28 ± 16.7             | 78.8 ± 26.21            | 0.026       |
| Aspirin (use)        | 28 (6.2%)                | 21 (13.5%)               | 4 (14.3%)               | 0.009       |
| ACEI/ARBs (use)      | 45 (10%)                 | 31 (20%)                 | 6 (21.4%)               | 0.002       |
| Beta-Blockers (use)  | 24 (5.3%)                | 9 (5.8%)                 | 1 (3.6%)                | 0.887       |
| Amlodipine (use)     | 29 (6.4%)                | 15 (9.7%)                | 3 (10.7%)               | 0.323       |
| Diuretics (use)      | 46 (10.2%)               | 16 (10.3%)               | 5 (17.9%)               | 0.436       |
| Insulin (use)        | 7 (1.5%)                 | 7 (4.5%)                 | 2 (7.1%)                | 0.035       |
| Metformin (use)      | 30 (6.6%)                | 18 (11.6%)               | 4 (14.3%)               | 0.072       |
| Sulfonylurea (use)   | 21 (4.6%)                | 13 (8.4%)                | 2 (7.1%)                | 0.208       |
| Simvastatin (use)    | 45 (10%)                 | 15 (9.7%)                | 3 (10.7%)               | 0.985       |
| Gemfibrozil (use)    | 13 (2.9%)                | 5 (3.2%)                 | 2 (7.1%)                | 0.454       |

Data presents as mean±SD and number with percentage

BMI Body mass index, BP Blood pressure, DM Diabetes mellitus, eGFR Estimated glomerular filtration rate, ACEI/ARBs Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers. All variables are at baseline level
CI 1.2–3.6, \( P=0.009 \)) However, macroalbuminuria with 1.92-fold risk might be counted as “clinically significant” factor in multivariate model (adjusted HR 1.92; 95% CI 0.9–4.08, \( P<0.09 \)) (Table 6).

Kaplan–Meier analysis illustrates the consecutively lower survival rate according to higher level of albuminuria for both composite outcomes, with the prominent effect among macroalbuminuria group (log-rank test, \( P<0.001 \), Fig. 2a and log-rank test, \( P=0.017 \), Fig. 2b).

**Discussion**

The 14-year retrospective cohort study showed that urine albumin related to cardiovascular, renal and mortality outcomes. Although, there were other cardiovascular risk factors at baseline, macroalbuminuria still manifested the independent association of cardiovascular and renal complications in primary composite outcome when compared with normoalbuminuria and microalbuminuria.

Results from clinical outcomes, incident density and Kaplan–Meier curve were consistent with previous studies which conducted in diabetic setting. The higher degree of albuminuria had a significant association with higher cardiovascular [23], renal [25] and all-cause mortality [23, 25]. Microalbuminuria had a slightly significant association to the outcome compared with normal urine albumin group while gross albuminuria group had a profound risk.

In this study, multivariate analysis of cox regression model for both composite outcomes did not show microalbuminuria as an independent risk factor. Some prior studies, mostly in diabetes, found that microalbuminuria was not independent risk of cardiovascular [26–31] and mortality [32] outcome as well. On the other hand, significant associations between microalbuminuria and cardiovascular morbidity or mortality [8, 23, 28, 33] and also total mortality [34–44] were reported. For renal outcome, a study by Berhane et al. [25] reported significant association with 2.1 times adjusted hazard ratio (HR) between end-stage renal disease (ESRD) and microalbuminuria when compared with normoalbuminuria. However, most of these studies’ population were diabetic.

Our findings revealed that macroalbuminuria had 3.13-fold higher risk than normoalbuminuria for cardiovascular or renal morbidity and mortality (adjusted HR 3.13; 95% CI 1.4–6.96, \( P=0.005 \)). It is likely that macroalbuminuria was associated with secondary composite outcome which included all-cause mortality (adjusted HR 1.92; 95% CI 0.9–4.08, \( P=0.09 \)). Prior studies showed either significant [42, 45–47] or no [27, 33, 40] association between macroalbuminuria and cardiovascular mortality. Whereas, a number of studies found the association between macroalbuminuria and all-cause mortality [34, 36, 37, 43, 48–53]. For renal outcome, several landmark studies discovered albuminuria as risk of ESRD [54–57], especially macroalbuminuria that had 9.3 times higher of ESRD incidence than normoalbuminuria [25].

Aging, hypertension, aspirin and metformin also revealed the independent relationship to the outcomes. Increased age definitely associated with prevalence and progression of non-communicable disease [58–60], cardiovascular event [61–63] and mortality [64].

**Table 2 Clinical outcomes according to urine albumin status**

| Urine albumin status                  | Primary Composite Outcomes | Cardiovascular events (ischemic heart disease, HF, PVD, stroke and cardiovascular death) | Renal events (ESRD, dialysis and renal death) | Overall mortality |
|--------------------------------------|-----------------------------|------------------------------------------------------------------------------------------|-----------------------------------------------|-------------------|
|                                      | Normoalbuminuria | Microalbuminuria | Macroalbuminuria | Normoalbuminuria | Microalbuminuria | Macroalbuminuria | Normoalbuminuria | Microalbuminuria | Macroalbuminuria |
|--------------------------------------|-----------------------------|------------------------------------------------------------------------------------------|-----------------------------------------------|-------------------|
| Primary Composite Outcomes           | 59 (13.1%)                  | 32 (20.6%)                                | 11 (39.3%)                                   | < 0.001           |
| Cardiovascular events                | 48 (10.6%)                  | 22 (14.2%)                                | 7 (25%)                                      | 0.051             |
| Renal events                         | 19 (4.2%)                   | 8 (5.2%)                                  | 7 (25%)                                      | < 0.001           |
| Overall mortality                    | 70 (15.5%)                  | 22 (14.2%)                                | 8 (28.6%)                                    | 0.151             |

Primary composite outcome includes cardiovascular or renal morbidity and mortality. International Classification of Diseases 10 (ICD-10) codes were identified in the hospital database to collect the outcome from EMR. Cardiovascular event was defined as ICD-I00 to ICD-I52 or ICD-I60 to ICD-I69. Renal event was defined as ICD-N00 to N19 or eGFR lower than 15 mL/min/1.73 m2 or initiation of renal replacement therapy.

HF Heart failure, PVD Peripheral vascular disease, ESRD End-stage renal disease.

**Table 3 Incident density of primary composite outcome (/1000 person-years)**

| Primary composite outcome | Person-year (year) | Primary composite outcome (n) | Incident density (/1000 person-years) | 95% CI       |
|---------------------------|-------------------|-------------------------------|---------------------------------------|-------------|
| Normoalbuminuria          | 5127.92           | 48                            | 9.36                                  | 7.05–12.42  |
| Microalbuminuria          | 1695.25           | 29                            | 17.11                                 | 11.89–24.62 |
| Macroalbuminuria          | 288.58            | 11                            | 38.12                                 | 21.11–68.83 |
| Total                     | 7111.75           | 88                            | 12.37                                 | 10.04–15.25 |

Primary composite outcome includes cardiovascular or renal morbidity and mortality.
Hypertension and diabetes are established risk factors in cardiovascular and renal diseases [65, 66]. We had high proportion of hypertensive subjects at baseline that possibly have an impact on the outcome. Besides, small proportion of type 2 diabetes at baseline could explain why it did not have significant risk to the outcomes. Even though this study does not have baseline fasting plasma glucose, hemoglobinA1c or duration of diabetes to indicate the severity of disease, small amount of insulin use could roughly tell that overall subjects were not poorly controlled diabetes. Therefore, effect of hyperglycemia might not participate much in the outcome’s pathogenesis.

Aspirin had highest magnitude of association in both composite outcomes (adjusted HR 5.28; 95% CI 2.75–10.14) (adjusted HR 2.08; 95% CI 1.2–3.6, $P = 0.009$). Although aspirin is a protective medication for cardiovascular complication [67], this result could be explained by the individuals who took aspirin either for primary or secondary prevention at baseline reflects to their own high cardiovascular risk compared to the person who did not. Furthermore, drug compliance was not assessed in this study which poor compliance is common among patient receiving low-dose aspirin [68].

Some studies suggested that metformin could have benefit in cardiovascular morbidity and mortality [69].

Table 4 Incident density of secondary composite outcome (/1000 person-years)

| Secondary composite outcome | Person-year (year) | Secondary composite outcome (n) | Incident density (/1000 person-years) | 95% CI |
|-----------------------------|--------------------|---------------------------------|---------------------------------------|------|
| Normoalbuminuria            | 5269               | 109                             | 20.69                                 | 17.15–24.96 |
| Microalbuminuria            | 1733.50            | 43                              | 24.81                                 | 18.40–33.45 |
| Macroalbuminuria            | 288.58             | 13                              | 45.05                                 | 26.16–77.58 |
| Total                       | 7291.08            | 165                             | 22.63                                 | 19.43–26.36 |

Secondary composite outcome includes cardiovascular or renal morbidity and all-cause mortality

Table 5 Univariate and multivariate of primary composite outcome

| Baseline variables | Univariate | Multivariate |
|--------------------|------------|--------------|
|                    | Crude HR (95%CI) | p-value | Adjusted HRa (95%CI) | p-value |
| Normoalbuminuria   | Reference | 1 | Reference | 1 |
| Microalbuminuria   | 1.82 (1.15, 2.89) | 0.011 | 1.4 (0.8, 2.44) | 0.235 |
| Macroalbuminuria   | 4.09 (2.12, 7.88) | < 0.001 | 3.13 (1.4, 6.96) | 0.005 |
| Age (years)        | 1.04 (1.02, 1.05) | < 0.001 | 1.02 (1, 1.05) | 0.084 |
| Male (%)           | 1.55 (1.02, 2.36) | 0.04 | 1.26 (0.74, 2.15) | 0.397 |
| BMI (kg/m²)        | 1.02 (0.96, 1.08) | 0.498 | |
| Systolic BP (mmHg) | 1.01 (0.99, 1.02) | 0.266 | |
| Diastolic BP (mmHg) | 1 (0.98, 1.02) | 0.867 | |
| History of Hypertension | 3.26 (2.14, 4.95) | < 0.001 | 2.6 (1.35, 5) | 0.004 |
| History of Type2 DM | 3.18 (1.95, 5.19) | < 0.001 | 1.64 (0.48, 5.66) | 0.43 |
| History of Dyslipidemia | 1.6 (0.85, 3.02) | 0.143 | |
| History of smoking (%) | 1.33 (0.82, 2.16) | 0.249 | |
| Serum creatinine (mg/dL) | 3.85 (1.53, 9.68) | 0.004 | |
| eGFR (ml/min/1.73m²) | 0.96 (0.97, 0.99) | < 0.001 | 0.99 (0.98, 1.01) | 0.365 |
| Aspirin (use)       | 6.73 (4.33, 10.49) | < 0.001 | 5.28 (2.75, 10.14) | < 0.001 |
| ACEI/ARBs (use)     | 2.86 (1.79, 4.57) | < 0.001 | 0.64 (0.32, 1.27) | 0.204 |
| Insulin (use)       | 5.67 (2.84, 11.31) | < 0.001 | 1.19 (0.42, 3.4) | 0.738 |
| Metformin (use)     | 2.41 (1.36, 4.28) | 0.003 | 0.29 (0.09, 0.94) | 0.038 |

Primary composite outcome includes cardiovascular or renal morbidity and mortality

BMI Body mass index, BP Blood pressure, DM Diabetes mellitus, eGFR Estimated glomerular filtration rate, ACEI/ARBs Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers. All variables are at baseline level

aAdjusted by age, gender, type 2 diabetes, hypertension, eGFR, Aspirin, ACEI/ARBs, Insulin and Metformin
Using metformin at baseline showed risk reduction in primary composite outcome, but not secondary composite outcome.

A strength of the present study was the duration of outcome measurement and ability to detect outcome completely because of small community. Several limitations were noted. The relatively small sample size of our cohort study is the main limitation. There was lacking of urine creatinine concentration and 24-h urine albumin, we cannot evaluate urine albumin-to-creatinine ratio (UACR) or albumin excretion rate to avoid the effect of morning urine hyperconcentration after a night fast. This study was conducted in a primary care hospital in rural Thailand where limited oral anti-hypertensive and diabetic medications were available. Drug compliance and duration of drug use were not evaluated in our cohort study is the main limitation.

**Table 6 Univariate and multivariate of secondary composite outcome**

| Baseline variables | Univariate | Multivariate |
|--------------------|------------|--------------|
|                    | Crude HR (95%CI) | p-value | Adjusted HRa (95%CI) | p-value |
| Normoalbuminuria   | Reference | 1 | Reference | 1 |
| Microalbuminuria   | 1.2 (0.84, 1.71) | 0.312 | 1.14 (0.75, 1.73) | 0.549 |
| Macroalbuminuria   | 2.23 (1.26, 3.97) | < 0.001 | 1.92 (0.9, 4.08) | 0.09 |
| Age (years)        | 1.04 (1.03, 1.06) | < 0.001 | 1.05 (1.02, 1.07) | < 0.001 |
| Male (%)           | 1.45 (1.07, 1.97) | 0.016 | 1.21 (0.82, 1.79) | 0.335 |
| BMI (kg/m²)        | 1.02 (0.97, 1.07) | 0.414 |
| Systolic BP (mmHg) | 1 (0.99, 1.01) | 0.44 |
| Diastolic BP (mmHg)| 0.99 (0.98, 1.01) | 0.439 |
| History of Hypertension | 2.08 (1.53, 2.84) | < 0.001 | 1.9 (1.16, 3.11) | 0.011 |
| History of Type2 DM | 2.12 (1.43, 3.15) | < 0.001 | 1.59 (0.6, 4.2) | 0.346 |
| History of Dyslipidemia | 1.08 (0.63, 1.83) | 0.786 |
| History of smoking (%) | 1.18 (0.82, 1.7) | 0.373 |
| Serum creatinine (mg/dL) | 2.92 (1.35, 6.3) | 0.007 |
| eGFR (ml/min/1.73m²) | 0.98 (0.97, 0.99) | < 0.001 | 1 (0.99, 1.01) | 0.817 |
| Aspirin (use)      | 3.21 (2.17, 4.75) | < 0.001 | 2.08 (1.2, 3.6) | 0.009 |
| ACEI/ARBs (use)    | 1.93 (1.32, 2.81) | 0.001 | 0.93 (0.53, 1.61) | 0.786 |
| Insulin (use)      | 3.42 (1.8, 6.49) | < 0.001 | 1.13 (0.47, 2.7) | 0.785 |
| Metformin (use)    | 1.8 (1.15, 2.83) | 0.01 | 0.47 (0.18, 1.25) | 0.131 |

Secondary composite outcome includes cardiovascular or renal morbidity and all-cause mortality

BMI Body mass index, BP Blood pressure, DM Diabetes mellitus, eGFR Estimated glomerular filtration rate, ACEI/ARBs Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers. All variables are at baseline level

aAdjusted by age, gender, type 2 diabetes, hypertension, eGFR, Aspirin, ACEI/ARBs, Insulin and Metformin

Fig. 2 a Kaplan-Meier curve for primary composite outcome according to urine albumin status (log rank test < 0.001). b Kaplan-Meier curve for secondary composite outcome according to urine albumin status (log rank test = 0.017)
retrospective study. Demographic data of subjects who had missing information of dipstick albumin should be measured and compared with the enrolled subjects. Laboratory variables, especially fasting plasma glucose, hemoglobinA1c and lipid profile, were not collected and measured at baseline. Moreover, laboratory data the end of study should be collected as well to assess the change and to be able to create some variable as the outcomes, for example, rapid renal progression. A systemic bias in laboratory measures in urine dipstick and serum creatinine possibly existed. Finally, the generalizability of our findings might be limited by the selection of middle-aged group and subjects living in rural areas of Thailand.

Conclusion
This study suggests that macroalbuminuria is an independent risk factor for cardiovascular and renal complications, but microalbuminuria is not. Albuminuria from semi-quantitative methods is an important factor predicting cardiovascular and renal risk among subjects in Thai rural population. Our findings support to also incorporating urine albumin dipstick into assessments of cardiovascular risk in the general population.

Acknowledgements
We thank the community “Baan Nayao” Moo 15 Thakadan, Sanamchaikhet, Chacherngsao, Thailand, staff from Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand, Phramongkutklao College of Medicine class 26th and 38th for patient's enrollment and data acquisition. The authors wish to acknowledge Ms. Dollapas Punpanich for statistical analysis.

Authors' contributions
N.A., KP, SS, KG, KV, TJ, SJ, KC, VP, NH, CJ, TP, TT, TC, PP, CW, PS, N.H., and A.K. collected the data and reviewed the literature. N.A., W.K., RR, and B.S. provided valuable input in study design, data collection, drafted the article and revised it critically. All authors read and approved the manuscript and met the criteria for authorship.

Funding
No funding was received.

Availability of data and materials
The dataset analyzed is available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocol was approved by the Institutional Review Board of Royal Thai Army Medical Department's committee on human research, approval number is R07/758, and written informed consent was obtained from all subjects with the WMA Declaration of Helsinki–Ethics principles for medical research involving human subjects.

Consent for publication
Not applicable.

Competing interests
The authors declare that no potential conflict of interest exists.

Author details
1Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand. 2Department of Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand.

References
1. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340(8815):319–23.
2. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbebe DE, Crijs HJ, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249(6):219–26.
3. Ørny PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011;54(1):32–43.
4. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn study. Arterioscler Thromb Vasc Biol. 1999;19(3):617–24.
5. Astor BC, Matsushita K, Gansvoort RT, van der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331–40.
6. Sarnak MJ, Astor BC. Implications of proteinuria: CKD progression and cardiovascular outcomes. Adv Chronic Kidney Dis. 2011;18(4):258–66.
7. Ageewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol. 1997;80(2):164–9.
8. Ommeren SF, Herbing HG. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157(13):1413–8.
9. Tonelli M, Muntner P, Lloyd A, Manns BJ, James MT, Klaarenbach S, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med. 2011;154(1):12–21.
10. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Microalbuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–21.
11. Targher G, Zoppini G, Chonchol M, Negri C, Stoico V, Pierro F, et al. Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutr Metab Cardiovasc Dis. 2011;21(4):294–301.
12. Schrader J, Luders S, Kulschevski A, Hammersen F, Zuchner C, Venneklaas CE. Reduction in albuminuria translates to reduction in cardiovascular and renal outcomes in patients with left ventricular hypertrophy and diabetes. J Nephrol. 2008;21(4):566–9.
13. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777–82.
14. Koutedakis Y, Koutedakis G, Iqbal K, Hageman RM, Kaptein E, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population: the Takahata study. Clin Exp Nephrol. 2011;15(7):805–10.
15. Koutedakis Y, Koutedakis G, Iqbal K, Hageman RM, Kaptein E, et al. Albuminuria is an independent predictor of all-cause and cardiovascular mortality in the Japanese population: the Takahata study. Clin Exp Nephrol. 2011;15(7):805–10.
16. Koutedakis Y, Koutedakis G, Iqbal K, Hageman RM, Kaptein E, et al. Albuminuria is an independent predictor of all-cause and cardiovascular mortality in the Japanese population: the Takahata study. Clin Exp Nephrol. 2011;15(7):805–10.
17. Grimm RH Jr, Svendsen KH, Kasibhe B, Keane WF, Wahi MM. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRRIT Research Group. Multiple Risk Factor Intervention Thal. Kidney Int Suppl. 1997;35:S10–4.
65. Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013;61(5):943–7.
66. Lea JP, Nicholas SB. Diabetes mellitus and hypertension: key risk factors for kidney disease. J Natl Med Assoc. 2002;94(8 Suppl):7S–15S.
67. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004;25(2):166–81.
68. Herlitz J, Toth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10(2):125–41.
69. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.